About
Chengdu Biostar
Pharmaceuticals Industrialization Base
Pharmaceuticals Industrialization Base
Beijing Biostar Pharmaceuticals' wholly-owned subsidiary Chengdu Biostar Pharmaceuticals has built a anti-tumor innovative product manufacturing base and a synthetic biology transformation base in the Western Zone of Chengdu High-tech Zone, occupying an area of 53,333 square meters, with an initial investment of RMB 500 million. It covers both API and DP and is in conformity with global GMP standards.
The industrialization production base of Chengdu Biostar Pharmaceuticals includes an anti-tumor pharmaceuticals plant, a quality inspection laboratory building, a pilot-scale production building, an oral formulation plant and a warehouse, and is equipped with world-class and national-class process equipment, analytical instruments, water system, air conditioning system, online monitoring system and safety control system. The first phase of the industrialization project has passed the GMP inspection in 2020. In the future, the production and transformation base is planned to meet the US and EU cGMP standards.
Adhering to the principle that "Quality is vital to the life of patients; quality is the soul of the corporate", Chengdu Biostar Pharmaceuticals has established a drug quality system in line with domestic and international standards, which is systematically implemented throughout the life cycle from drug development, technology transfer, production, to post-marketing management.
Chengdu Biostar Pharmaceuticals adheres to the following principles: "careful design and technological innovation" in R&D, "system improvement and risk control" in production, and "honesty, trustworthiness, and keeping up with the times" in business operations.